Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab

Human Antibodies

Volumn 18, Issue 4, 2009, Pages 127-137

  Glassy, Mark C ^a,b,c   Hagiwara, Hideaki ^a  

^a Hagiwara Institute of Health Integrated Medical Sciences Association Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Nascent Biologics Inc   (United States)

Author keywords

Clinical trials; Glioblastoma; Human antibody; Neuroimmunology; Pritumumab

Indexed keywords

DAUNORUBICIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PRITUMUMAB; PRITUMUMAB I 131; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; ASTROCYTOMA; BRAIN CANCER; BRAIN TUMOR; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; GLIOBLASTOMA; GLIOMA; HUMAN; JAPAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; FEMALE; GLIOMA; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; JAPAN; MALE; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 75149146510     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2009-0209     Document Type: Article

References (44)

1. M. Dougan and G. Dranoff, Immune therapy for cancer, Ann Rev Immunol 27 (2009), 83-117.
2. A.L. Nelson and J.M. Reichert, Development trends for therapeutic antibody fragments, Nature Biotech 27 (2009), 331-337.
3. M.C. Glassy, H.H. Handley, H. Hagiwara and I. Royston, UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc. Natl, Acad Sci 80 (1983), 6327-6331.
4. H. Hagiwara and G.H. Sato, Human x human hybridomas producing monoclonal antibody against autologous cervical carcinoma, Mol Biol Med 1 (1983), 245-252.
5. M.C. Glassy, Immortalization of human lymphocytes from a tumor involved lymph node, Cancer Res 47 (1987), 5181-5188.
6. M.C. Glassy and M.E. McKnight, A novel drug discovery programme utilizing the human immune response, Curr Opin Invest Drugs 2 (1993), 853-858.
7. M.C. Glassy and M.E. McKnight, Pharming the human lymph node, Exp Opin Invest Drugs 3 (1994), 1057.
8. M. Glassy, M. McKnight, B. Kotlan, E. Glassy and K. Koda, Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts, Human Antibod 16 (2007), 87-98.
9. H. Hagiwara and J. Nagao, Preferential generation of IgGproducing human hybridomas against human tumor cells, J Immunol Meth 135 (1990), 263-271.
10. H. Hagiwara, The production of anti-cancer human monoclonal antibody, Biosci Indust 48 (1990), 19-28, [in Japanese].
11. H. Hagiwara, Human x human hybridomas and production of anti-cancer human monoclonal antibodies (1), Bio Industry 4 (1987), 622-631, [in Japanese].
12. H. Hagiwara, Human x human hybridomas and production of anti-cancer human monoclonal antibodies (2), Bio Industry 4 (1987), 730-740, [in Japanese].
13. H. Hagiwara, Human x human hybridomas and production of anti-cancer human monoclonal antibodies (3), Bio Industry 4 (1987), 808-817, [in Japanese].
14. H. Hagiwara and Y. Aotsuka, Cytotoxicity of mixed human monoclonal antibodies reacting to tumor antigens, Acta Paediatr Jpn 29 (1987), 552-556.
15. H. Hagiwara, Suppression of tumor cell proliferation by use of a human monoclonal antibody, Immunopharmacol Therapy 7 (1989), 497-503, [in Japanese].
16. N. Umesaki, M. Kawabat, Y. Kanaoka, K.Tuda, T. Sugawa and T. Asada, Reactivity and cytotoxicity of human monoclonal antibody (CLN-IgG) to the gynecological malignancies, J Jpn Soc Cancer Ther 26 (1991), 14-20, [in Japanese].
17. K. Tawamoto, A. Ijichi, S. Matsumoto and H. Hagiwara, Antitumor effects of human monoclonal antibodies on human malignant glioma xenografts and their clinical application, in: Biological Aspects of Brain Tumors, K. Tabuchi, ed., Springer- Verlag, 1991, pp. 452-463.
18. K. Osumi, J. Nagao, H. Yuasa, H. Fujimoto, H. Hagiwara, Y. Kodera and R. Ohno, Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody, Cancer Lett 62 (1992), 179-183.
19. Y. Aotsuka and H. Hagiwara, Identification of a malignant cell associated antigen recognized by a human monoclonal antibody, Eur J Cancer Clin Oncol 24 (1988), 829-838.
20. T. Kokunai, N. Tamaki and S. Matsumoto, Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody, J Neurosurg 73 (1990), 901-908.
21. H. Hagiwara, J. Nagao, Y. Yamamoto and Y. Aotsuka, Human monoclonal antibody CLN-IgG recognizing TA226 malignant tumor-associated antigen: their paratope-epitope structures and idiotype image transmission in brain tumor patients, Res Neuroimmunity 7 (1994), 242-249, [in Japanese].
22. M. Nagai, J. Narita, S. Okuhata, K. Watanabe, M. Endo, C. Ochiai and H. Hagiwara, Correlation between clinical effect of CLN-IgG and induction of anti-anti-idiotypic antibody in the serum of glioma patient, Neuroimmunol Res 7 (1994), 253-257, [in Japanese].
23. M. Nagai, J.-I. Narita, K.Watanabe, M. Endoh, C. Ochiai and H. Hagiwara, Clinical effects of CLN-IgG on glioma and its correlation with the induction of antianti-idiotypic antibody in the serum, in: Brain Tumor Research and Therapy, M. Nagai, ed., Springer-Verlag, 1996, pp. 381-387.
24. H. Hagiwara and Y. Aotsuka, Structural analysis of anti-cancer antibody, CLN-IgG, and anti-idiotypic antibody, Idio-No. 3, for the study of idiotope image transmission: an insight into antigen-specific human monoclonal antibody therapy, in: Brain Tumor Research and Therapy, M. Nagai, ed., Springer- Verlag, 1996, pp. 371-379.
25. Y. Kobayashi, T. Baba, H. Yamazaki, Y. Yamazaki, K. Kuwata and H. Hagiwara, Enzyme immunohistochemical study using human x human hybridomas producing monoclonal antibody against autologous stomach carcinoma on frozen sections of stomach carcinoma and non-tumorous stomach mucosa, Ann Bull Kosei-Nenkin Hosp 15 (1988), 373-378, [in Japanese].
26. M. Nagai, T. Arai, K. Watanabe, K. Ichikawa and T. Watari, Clinical application of radiolabeled human x human monoclonal antibody with interferon in the treatment of malignant glioma - preliminary report. "Neuro- Oncology" (ed P Paoletti et al.) Kluwer Academic Publishers, 1991, pp. 153-159.
27. H. Hagiwara and H. Yuasa, Anti-cancer human monoclonal antibodies - for understanding their clinical use for brain tumors, Curr Practical Neurosurg 3 (1993), 653-660, [in Japanese].
28. M. Nakada, S. Nakada, T. Denmuth, N.L. Tran, D.B. Hoelzinger and M.E. Berens, Molecular targets of glioma invasion, Cell Mol Life 64 (2007), 458-478.
29. M. Nagai, T. Arai, K. Watanabe, K. Ichikawa and T. Watari, Clinical application of I-131 labeled human monoclonal antibody CLN-IgG on recurrent malignant glioma - preliminary report, Neuroimmunological Research 3 (1990), 123-127, [in Japanese].
30. S. Matsumoto, T. Kokunai, N. Tamaki, R. Tanaka, H. Takahashi, S. Nakazawa, M. Nagai, Y. Oda, H. Kikuchi, H. Fukui, K. Tabuchi, Y. Ushio and F. Ikuta, Clinical Phase 1 study of human monoclonal antibody, ACA-11 (CLN-IgG) against human malignant brain tumors, The Clinical Report 28 (1994), 1059-1064, [in Japanese].
31. S. Masumoto, M. Nagai, H. Takahashi, S. Nakazawa, K. Taka kuras, M. Matsutani, R. Tanaka, J. Yamashita, T. Kobayashi, Y. Oda, H. Kikuchi, T. Kokunai, N. Tamaki, K. Taomoto, H. Fukui, K. Tabuchi and Y. Ushio, Early Phase II study of human monoclonal antibody, ACA-11 (CLN-IgG), against malignant brain tumors, The Clinical Report 28 (1994), 1065-1073, [in Japanese]
32. K. Taomoto, A. Ijichi, T. Sasayama, S. Tatsumi, J. Nagao and H. Hagiwara, Immunotherapy for glioma patients with human monoclonal antibody - therapeutical effects and immunological network, Neuroimmunol Res 9 (1996), 99-105, [in Japanese].
33. T. Iwakoshi, T. Kobayashi, Y. Kida, T. Tanaka, H. Oyama, M. Niwa and R. Kitamura, Results of an immunotherapy using human monoclonal antibody for gliomas: findings in ten cases, Jpn J Neurosurg 5 (1996), 266-271, [in Japanese].
34. T. Kokunai, H. Tomita, S. Urui, N. Tamaki and S. Matsumoto, Clinical late phase II study of human monoclonal antibody (ACA11) against human glioma, Neuroimmunological Res 12 (1999), 171-174, [in Japanese].
35. T. Kokunai, Anti-TA226 human monoclonal antibody (ACA- 11) against glioma, Nippon Rinsho 60 (2002), 100-106.
36. M.C. Glassy, R.E. Peters and A. Mikhalev, Growth of humanhuman hybridomas in serum-free media enhances antibody secretion, InVitro 23 (1987), 745-749.
37. H. Hagiwara, H. Ohtake, H. Yuasa, J. Nagao, S. Nonaka, E. Chigiri and Y. Aotsuka, Proliferation and antibody production of human x human hybridoma in serum-free media. Proc, in: Intl Symp Growth and Differentiation of Cells in Defined Environment, H. Murakami, I. Yamane, D.W. Barnes, J.P. Mather, I. Hayashi and G.H. Sato, eds, Springer-Verlag, 1985, pp. 117-122.
38. H. Hagiwara and E. Aotsuka, Serum-free cultivation of human x human hybridoma, Bio Industry 13 (1986), 717-725, [in Japanese].
39. H. Hagiwara and H. Yuasa, Generation of somatic cell hybrids capable of proliferating and secreting human monoclonal antibody without any growth factor supplements, Hum Antibod Hybridomas 4 (1993), 15-19.
40. Y. Aotsuka and M. Naito, Enhancing effects of retinoic acid on monoclonal antibody production of human-human hybridomas, Cell Immunol 133 (1991), 498-505.
41. T. Kokunai, N. Tamaki and S. Matsumoto, Distribution and pharmacokinetics of human monoclonal antibody in nude mice implanted with malignant glioma cells, Neuroimmunological Res 3 (1990), 128-133, [in Japanese].
42. H. Hagiwara, Y. Aotsuka, Y. Yamamoto, Miyahara and Y. Mitoh, Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG, Human Antibodies 10 (2001), 77-82.
43. Y. Tajika, O. Kubo and K. Takakura, Human monoclonal antibody and a therapeutic agent for cancer - immunotherapy for brain tumor, Pharmacia 33 (1997), 34-37, [in Japanese].
44. H. Takahashi, F. Yamaguchi and S. Nakazawa, An experimental study on monoclonal antibody and cytokine on human malignant glioma, Soc Study Brain Immunity Neuroimmunol Res 3 (1990), 114-118, [in Japanese].